We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
+4.75%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$410M
AUM Growth
+$3.58M
(+0.88%)
Cap. Flow
-$16.8M
Cap. Flow
% of AUM
-4.11%
Top 10 Holdings %
Top 10 Hldgs %
72.55%
Holding
40
New
17
Increased
1
Reduced
10
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$38.6M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$36.8M |
| 3 |
AGN.PRA
Allergan plc
AGN.PRA
|
+$36.2M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$27.2M |
| 5 |
Encompass Health
EHC
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$35.2M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$34.5M |
| 3 |
Eli Lilly
LLY
|
+$34.2M |
| 4 |
ESRX
Express Scripts Holding Company
ESRX
|
+$33.1M |
| 5 |
Gilead Sciences
GILD
|
+$26.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Halozyme
HALO
$9.23B
| $66.5M | 16.24% |
3,830,190
-257,074
| -6% | -$3.48M |
|
|
2
Sanofi
SNY
$105B
| $39.7M | 9.69% |
+797,486
| New | +$38.6M |
|
|
3
Regeneron Pharmaceuticals
REGN
$68.3B
| $34.6M | 8.44% |
+77,300
| New | +$36.8M |
|
|
AGN.PRA
4
DELISTED
Allergan plc
AGN.PRA
| $32.2M | 7.85% |
+43,600
| New | +$36.2M |
|
|
TSRO
5
DELISTED
TESARO, Inc.
TSRO
| $28.3M | 6.92% |
+219,500
| New | +$27.2M |
|
|
EXAS
6
PUT
DELISTED
Exact Sciences
EXAS
| $27.1M | 6.6% |
+658,000
| New | +$26.5M |
|
7
Elevance Health
ELV
$84.4B
| $24.1M | 5.87% |
126,700
-17,650
| -12% | -$3.36M |
|
|
8
Encompass Health
EHC
$11B
| $21.3M | 5.2% |
+577,717
| New | +$20.6M |
|
|
AGN
9
DELISTED
Allergan plc
AGN
| $12.3M | 3.01% |
+60,100
| New | +$14M |
|
|
AERI
10
DELISTED
Aerie Pharmaceuticals
AERI
| $11.2M | 2.74% |
231,200
-160,200
| -41% | -$8.74M |
|
11
TG Therapeutics
TGTX
$8.06B
| $10.2M | 2.5% |
863,500
-105,800
| -11% | -$1.21M |
|
12
Globus Medical
GMED
$10.2B
| $9.79M | 2.39% |
+329,400
| New | +$10.1M |
|
13
Medtronic
MDT
$105B
| $9.58M | 2.34% |
+123,200
| New | +$10.2M |
|
|
CLVS
14
DELISTED
Clovis Oncology, Inc.
CLVS
| $9.26M | 2.26% |
+112,400
| New | +$8.91M |
|
15
Ironwood Pharmaceuticals
IRWD
$639M
| $8M | 1.95% |
+605,358
| New | +$8.33M |
|
|
ALDR
16
DELISTED
Alder Biopharmaceuticals
ALDR
| $7.85M | 1.92% |
641,170
+83,400
| +15% | +$870K |
|
17
Insmed
INSM
$23.1B
| $7.45M | 1.82% |
+238,700
| New | +$4.55M |
|
|
ESRX
18
DELISTED
Express Scripts Holding Company
ESRX
| $6.9M | 1.68% |
108,901
-532,400
| -83% | -$33.1M |
|
19
Universal Health Services
UHS
$9.04B
| $6.79M | 1.66% |
+61,200
| New | +$6.89M |
|
20
Pediatrix Medical
MD
$2.12B
| $6.6M | 1.61% |
+153,000
| New | +$7.27M |
|
21
Theravance Biopharma
TBPH
$871M
| $6.24M | 1.52% |
+182,100
| New | +$5.95M |
|
|
CNCE
22
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $4.95M | 1.21% |
335,445
-76,700
| -19% | -$1.11M |
|
|
CORI
23
DELISTED
Corium International, Inc.
CORI
| $4.93M | 1.2% |
445,166
-358,600
| -45% | -$3.17M |
|
|
ELGX
24
DELISTED
Endologix Inc
ELGX
| $4.02M | 0.98% |
+90,154
| New | +$4.11M |
|
25
Protagonist Therapeutics
PTGX
$8.71B
| $3.9M | 0.95% |
221,000
-52,500
| -19% | -$727K |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q3 2017 Portfolio in Review
As of Q3 2017, Senzar Asset Management held 40 positions worth $410M, up 0.88% from $406M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Senzar Asset Management withdrew a net $16.8M in Q3 2017, closing 12 positions and reducing 10 holdings. Its most notable exit was Viatris, an estimated $35.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 90% a quarter earlier.
Against the trend, Senzar Asset Management opened a new position in Sanofi worth $39.7M.
- Senzar Asset Management's largest Q3 2017 buy was Sanofi: 797,486 shares worth $39.7M.
- Senzar Asset Management added most to Alder Biopharmaceuticals in Q3 2017, an estimated $870K increase.
- Senzar Asset Management's biggest Q3 2017 reduction was Express Scripts Holding Company, cutting an estimated $33.1M.
- Senzar Asset Management fully exited Viatris in Q3 2017, selling an estimated $35.2M.
- Senzar Asset Management's ten largest holdings make up 73% of its $410M portfolio in Q3 2017.
- Senzar Asset Management opened 17 new positions and closed 12 in Q3 2017.
- Senzar Asset Management's portfolio value rose 0.88% quarter-over-quarter to $410M.
Based on Senzar Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.